Palmidrol | CAS# 544-31-0 | respiratory viral infection

MedKoo Cat#: 414742 | Name: Palmidrol

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Palmidrol is a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection.

Chemical Structure

Palmidrol

CAS#544-31-0

Theoretical Analysis

MedKoo Cat#: 414742

Name: Palmidrol

CAS#: 544-31-0

Chemical Formula: C18H37NO2

Exact Mass: 299.2824

Molecular Weight: 299.49

Elemental Analysis: C, 72.19; H, 12.45; N, 4.68; O, 10.68

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 450.00	2 Weeks
50mg	USD 800.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Palmidrol; NSC 23320; NSC23320; NSC-23320; Palmitoylethanolamide

IUPAC/Chemical Name

N-(2-Hydroxyethyl)hexadecanamide

InChi Key

HXYVTAGFYLMHSO-UHFFFAOYSA-N

InChi Code

InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)19-16-17-20/h20H,2-17H2,1H3,(H,19,21)

SMILES Code

CCCCCCCCCCCCCCCC(NCCO)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 299.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Rankin L, Fowler CJ. The Basal Pharmacology of Palmitoylethanolamide. Int J Mol Sci. 2020 Oct 26;21(21):7942. doi: 10.3390/ijms21217942. PMID: 33114698; PMCID: PMC7662788. 2: Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis. Pain Physician. 2017 Jul;20(5):353-362. PMID: 28727699. 3: Koltyn KF, Brellenthin AG, Cook DB, Sehgal N, Hillard C. Mechanisms of exercise-induced hypoalgesia. J Pain. 2014 Dec;15(12):1294-1304. doi: 10.1016/j.jpain.2014.09.006. PMID: 25261342; PMCID: PMC4302052. 4: Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012 Mar 20;2(3):e94. doi: 10.1038/tp.2012.15. PMID: 22832859; PMCID: PMC3316151. 5: Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016 Oct;82(4):932-42. doi: 10.1111/bcp.13020. Epub 2016 Jun 29. PMID: 27220803; PMCID: PMC5094513. 6: Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol. 2017 Jun;174(11):1349-1365. doi: 10.1111/bph.13580. Epub 2016 Sep 29. PMID: 27539936; PMCID: PMC5429331. 7: Adornetto A, Rombolà L, Morrone LA, Nucci C, Corasaniti MT, Bagetta G, Russo R. Natural Products: Evidence for Neuroprotection to Be Exploited in Glaucoma. Nutrients. 2020 Oct 16;12(10):3158. doi: 10.3390/nu12103158. PMID: 33081127; PMCID: PMC7602834. 8: Ye S, Chen Q, Jiang N, Liang X, Li J, Zong R, Huang C, Qiu Y, Ma JX, Liu Z. PPARα-Dependent Effects of Palmitoylethanolamide Against Retinal Neovascularization and Fibrosis. Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):15. doi: 10.1167/iovs.61.4.15. PMID: 32298438; PMCID: PMC7401460. 9: De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S, Stott CG, Di Marzo V. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011 Aug;163(7):1479-94. doi: 10.1111/j.1476-5381.2010.01166.x. PMID: 21175579; PMCID: PMC3165957. 10: Stensson N, Gerdle B, Ernberg M, Mannerkorpi K, Kosek E, Ghafouri B. Increased Anandamide and Decreased Pain and Depression after Exercise in Fibromyalgia. Med Sci Sports Exerc. 2020 Jul;52(7):1617-1628. doi: 10.1249/MSS.0000000000002293. PMID: 32168104.